On Jul. 14, 2020, NIH researchers reported early results from the first COVID-19 vaccine candidate tested in people showed that it triggered an immune response against the virus with no serious side effects. The vaccine, called mRNA-1273, is being co-developed by researchers at NIHﾒs National Institute of Allergy and Infectious Diseases (NIAID) and the biotech company Moderna.